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Abstract 
Dexmedetomidine is selective agonist for α2 receptors in the central nervous 
system and other organs. At present, it is used as a sedative and analgesic 
medicine after operations. Several studies have provided evidence for new 
mechanism of action of dexmedetomidine. Here we reviewed the current 
understanding about dexmedetomidine mechanism of action involved in 
neuroprotection and ischemia-reperfusion injuries. 
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Introduction 
Dexmedetomidine (PRECEDEX) is an 
imidazole derivative that is a highly selective α2 
receptor agonist. Activation of the α2 adrenergic 
receptors by dexmedetomidine leads to both sedation 
and analgesia; with negligible respiratory and 
cardiovascular side effects (1). Fresh experiments 
have provided evidence about neuroprotective 
properties of dexmedetomidine which can attenuate 
delirium, preserve sleep architecture and preserve 
ventilatory drive (2,3). Beyond its effects in the 
central nervous system, recent studies have shown 
efficacy of dexmedetomidine against ischemia-
reperfusion injury, and against injuries following 
organ transplantation (4, 5). 
α 2 receptor 
Dexmedetomidine is highly selective for α 2 
receptors. Analgesic effects of dexmedetomidine are 
achieved through negative feedback control found at 
the presynaptic level of autonomic function and in 
some cases in sensory neurons. Dexmedetomidine 
diminishes α 2 activation with release of 
norepinephrine from these nerve endings and other 
co-transmitters which are important in signal 
transduction (6, 7). Presynaptic that respond to the 
primary transmitter substance released by nerve 
ending are called auto-receptors (1). α 2 belongs to 
the family of G protein-coupled receptors (GPCRs). 
GPCRs are coupled by G proteins to the various 
effector proteins including phospholipase C (PLC) 
and adenylyl cyclase (AC) whose activities are 
regulated by those receptors. G protein is a 
heterotrimer consisting of α, β, and γ subunits. GPCR 
activation causes production of guanosine 
triphosphate (GTP) from guanosine diphosphate 
(GDP). GTP binds to α subunit and causes 
dissociation from two subunits. The activated GTP-
bound α subunit then regulates the activity of AC. α 2 
receptors inhibit adenylyl cyclase activity and cause 
decrease of cyclic adenosine monophosphate (cAMP) 
levels (8, 9). α 2–mediated inhibition of adenylyl 
cyclase use other signaling pathways, including 
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regulation of ion channel activities and the activities 
of important enzymes involved in signal transduction. 
In addition to CNS, receptors for α2 are found 
platelets, the liver, pancreas, kidney, eye and heart. 
From an anesthesiologist point of view, neuronal 
hyperpolarization is a key element in the mechanism 
of action of dexmedetomidine and is achieved by 
efflux of potassium and suppression of calcium entry. 
Loss of intracellular potassium and inhibition of 
calcium entry suppress neuronal firing and can inhibit 
signal transduction (10, 11). 
Dexmedetomidine  and 
neuroprotection 
There is an increasing concern regarding the 
risk of anesthetic-induced developmental 
neurotoxicity (AIDN) in children. Numerous studies 
in animals have shown that general anesthetic agents 
not only induce neuroapoptosis, but also affect other 
neurodevelopmental processes in the developing 
brain. Anesthetic exposure induces apoptosis and 
neurodegeneration in a dose and time-dependent 
fashion (12). In the developing brain, especially 
during synaptogenesis, the intracellular concentration 
of Cl− is high. Activation of GABA A receptor results 
in Cl− efflux and depolarization of the neuron. 
Depolarization mediates rise in intracellular calcium 
concentration, which reaches levels that can 
contribute to neuronal injury (13). Calcium overload 
triggers widespread apoptotic cell death in developing 
brain and eventually result in long-term 
neurobehavioral impairment (14). The mechanism of 
cell death triggered by anesthetic drugs involves 
translocation of Bax protein to the mitochondrial 
membranes, where it disrupts membrane 
permeability, allowing extra-mitochondrial leakage of 
cytochrome c, followed by a sequence of changes 
culminating in activation of caspase-3 (13,14). 
Dexmedetomidine neuroprotection appears to involve 
a decrease in caspase 3 levels, and reversal of 
isoflurane-induced decrease in anti-apoptotic Bcl-1, 
pERK1, and pERK2 protein expression in vivo (15). 
Neuro-inflammatory mediators such as cytokines may 
be involved in a number of key steps in the 
pathological cascade of events leading to anesthetic-
induced neuronal injury. Anesthesia can induce 
cytokines release in the central nervous system, 
leading to deleterious neurodevelopmental effect. A 
study by Laudenbach showed that dexmedetomidine 
exhibited dose-dependent protection against brain 
matter loss in vivo and improved the neurologic 
functional deficit induced by the hypoxic-ischemic 
insult by α2 activation (16). Another study by Tung 
revealed dexmedetomidine attenuates neuronal injury 
induced by maternal propofol anesthesia in the fetal 
brains, providing neurocognitive protection in the 
offspring rats (17). Anesthetic agents (e.g., isoflurane, 
propofol) may cause neurodegeneration in the 
developing brains and impair animals’ learning 
ability. In that study, administration of DEX 
significantly inhibited propofol-induced caspase-3 
activation and microglial response in the fetal brains 
showing anti-apoptotic effects of dexmedetomidine. 
On the other hand, the recent studies considering the 
effects of anesthetic drugs on processed 
electroencephalogram show that dexmedetomidine 
has the most similar pattern with normal sleep 
(18,19). These studies suggest that based on more 
sophisticated a clinical study considering the EEG 
patterns, dexmedetomidine has much more favorable 
than other anesthetic agents. Add to this point, the 
neuroprotective effects of dexmedetomidine which is 
associated with the least amount of neuroapoptosis in 





During reperfusion several important 
substances are released. Heat shock proteins (HSP) 
can propagate inflammatory responses possible 
through toll-like receptor 4 (TLR4). Oxidants activate 
a signal transduction cascade that may engage the 
cell-death pathway and provoke apoptosis. These 
factors contribute to development of reperfusion 
injury (20). Continued ischemia causes cellular 
accumulation of Ca2+ and generation of oxygen free 
radicals. Free radicals can directly damage 
mitochondria and subsequently lead to interruption in 
ATP synthesis and cell death (21). Kip’s work 
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showed that dexmedetomidine caused levels of 
catalase (CAT) and glutathione-S-transferase anti-
oxidant enzymes, and malondialdehyde (MDA) to 
decrease and reduced I/R injury of lungs in rat (22). 
In addition, Yushitimioi’s study demonstrated that 
dexmedetomidine reduced the incidence of 
reperfusion-induced ventricular arrhythmias in pigs 
(23). The inhibitory effect of DEX on the production 
of tumor necrosis factor-α (TNF-α) and interleukin 
IL-6 following endotoxin injection is noteworthy 
(24). DEX induces apoptosis of neutrophils and 
inhibits superoxide production by neutrophils in a 
dose dependent manner (25). A fresh experiment by 
Yao showed that pre-treatment with 
dexmedetomidine reduced kidney pathological injury, 
TLR4 expression, and cytokine production following 
orthotopic autologous liver transplantation (OALT) in 
rats (26). 
Conclusion 
Dexmedetomidine is able to reduce 
neuroapoptosis and neurodegeneration by its unique 
mechanism of action which varies extensively from 
its known sedative and analgesic effects. In addition, 
it has beneficial effects against I/R injuries 
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